Dasatinib: a Potential Tyrosine Kinase Inhibitor to Fight Against Multiple Cancer Malignancies

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2023 May 10

PMID 37165283

Authors

Fauziya

Akash Gupta

Arif Nadaf

Shadaan Ahmad

Nazeer Hasan

Mohammad Imran

Amirhossein Sahebkar

Gaurav Kumar Jain

Prashant Kesharwani

Farhan J Ahmad

Affiliations

Soon will be listed here.

Abstract

Dasatinib is the 2nd generation TKI (Tyrosine Kinase Inhibitor) having the potential to treat numerous forms of leukemic and cancer patients and it is 300 times more potent than imatinib. Cancer is the major cause of death globally and need to enumerate novel strategies to coping with it. Various novel therapeutics introduced into the market for ease in treating various forms of cancer. We reviewed and evaluated all the related aspects of dasatinib, which can enhance the knowledge about dasatinib therapeutics methodology, pharmacodynamic and pharmacokinetics, side effects, advantages, disadvantages, various kinds of interactions and its novel formulations as well.

Citing Articles

Aging and tumors: a dynamic interaction.

Zhang Y, Zhu S, Liu Z, Hu Y, Zhang Y, Shang L Discov Oncol. 2025; 16(1):68.

PMID: 39836268 PMC: 11751271. DOI: 10.1007/s12672-025-01808-9.

Halloysite Nanotube-Based Delivery of Pyrazolo[3,4-]pyrimidine Derivatives for Prostate and Bladder Cancer Treatment.

Massaro M, Ciani R, Grossi G, Cavallaro G, de Melo Barbosa R, Falesiedi M Pharmaceutics. 2024; 16(11).

PMID: 39598551 PMC: 11597611. DOI: 10.3390/pharmaceutics16111428.

Dronedarone hydrochloride inhibits gastric cancer proliferation in vitro and in vivo by targeting SRC.

Lu X, Zhang W, Yang X, Yan X, Hussain Z, Wu Q Transl Oncol. 2024; 50:102136.

PMID: 39369581 PMC: 11491965. DOI: 10.1016/j.tranon.2024.102136.

Targeting senescence-associated secretory phenotypes to remodel the tumour microenvironment and modulate tumour outcomes.

Xiong J, Dong L, Lv Q, Yin Y, Zhao J, Ke Y Clin Transl Med. 2024; 14(9):e1772.

PMID: 39270064 PMC: 11398298. DOI: 10.1002/ctm2.1772.

Dasatinib promotes muscle differentiation and disrupts normal muscle regeneration.

Ishida N, Kurosawa T, Goto M, Kaji N, Tokunaga Y, Mihara T Int J Med Sci. 2024; 21(8):1461-1471.

PMID: 38903922 PMC: 11186431. DOI: 10.7150/ijms.94938.

References

McCormack P, Keam S . Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs. 2011; 71(13):1771-95. DOI: 10.2165/11207580-000000000-00000. View

Niza E, Noblejas-Lopez M, Bravo I, Nieto-Jimenez C, Castro-Osma J, Canales-Vazquez J . Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer. Nanomaterials (Basel). 2020; 9(12). PMC: 6955794. DOI: 10.3390/nano9121793. View

Ongoren S, Eskazan A, Suzan V, Savci S, Erdogan Ozunal I, Berk S . Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature. Hematology. 2017; 23(4):212-220. DOI: 10.1080/10245332.2017.1385193. View

Montemurro M, Cioffi A, Domont J, Rutkowski P, Roth A, Von Moos R . Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07). Cancer. 2018; 124(7):1449-1454. DOI: 10.1002/cncr.31234. View

Lombardo L, Lee F, Chen P, Norris D, Barrish J, Behnia K . Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004; 47(27):6658-61. DOI: 10.1021/jm049486a. View

Blake S, Hughes T, Lyons A . Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A. Exp Hematol. 2012; 40(8):612-21.e6. DOI: 10.1016/j.exphem.2012.04.003. View

Mizuta S, Sawa M, Tsurumi H, Matsumoto K, Miyao K, Hara T . Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study. Int J Clin Oncol. 2018; 23(5):980-988. PMC: 6154123. DOI: 10.1007/s10147-018-1300-9. View

Kang B, Kim Y, Park T, Kang H . Dasatinib, a second-generation tyrosine kinase inhibitor, induces melanogenesis via ERK-CREB-MITF-tyrosinase signaling in normal human melanocytes. Biochem Biophys Res Commun. 2020; 523(4):1034-1039. DOI: 10.1016/j.bbrc.2020.01.051. View

Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M . Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2019; 126(1):67-75. PMC: 8529949. DOI: 10.1002/cncr.32504. View

10.

Vaidhyanathan S, Wang X, Crison J, Varia S, Gao J, Saxena A . Bioequivalence Comparison of Pediatric Dasatinib Formulations and Elucidation of Absorption Mechanisms Through Integrated PBPK Modeling. J Pharm Sci. 2018; 108(1):741-749. DOI: 10.1016/j.xphs.2018.11.005. View

11.

Santos T, Miranda A, Campello M, Paulo A, Salgado G, Cabrita E . Recognition of nucleolin through interaction with RNA G-quadruplex. Biochem Pharmacol. 2020; 189:114208. DOI: 10.1016/j.bcp.2020.114208. View

12.

Beck O, Paret C, Russo A, Burhenne J, Fresnais M, Steimel K . Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma. Cancers (Basel). 2020; 12(4). PMC: 7225940. DOI: 10.3390/cancers12040793. View

13.

Mezei G, Debreceni I, Kerenyi A, Remenyi G, Szasz R, Illes A . Dasatinib inhibits coated-platelet generation in patients with chronic myeloid leukemia. Platelets. 2018; 30(7):836-843. DOI: 10.1080/09537104.2018.1501470. View

14.

Leveque D, Becker G, Bilger K, Natarajan-Ame S . Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib. Clin Pharmacokinet. 2020; 59(7):849-856. DOI: 10.1007/s40262-020-00872-4. View

15.

Araujo J, Logothetis C . Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev. 2010; 36(6):492-500. PMC: 3940067. DOI: 10.1016/j.ctrv.2010.02.015. View

16.

Qin Q, Meng T, Tan M, Liu Y, Luo X, Zou B . Synthesis, crystal structure and biological evaluation of a new dasatinib copper(II) complex as telomerase inhibitor. Eur J Med Chem. 2017; 143:1597-1603. DOI: 10.1016/j.ejmech.2017.10.058. View

17.

Scuoppo C, Wang J, Persaud M, Mittan S, Basso K, Pasqualucci L . Repurposing dasatinib for diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2019; 116(34):16981-16986. PMC: 6708382. DOI: 10.1073/pnas.1905239116. View

18.

Gencer E, Ural A, Avcu F, Baran Y . A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes. Ann Hematol. 2011; 90(11):1265-75. DOI: 10.1007/s00277-011-1212-5. View

19.

Ishida Y, Murai K, Yamaguchi K, Miyagishima T, Shindo M, Ogawa K . Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia. Eur J Clin Pharmacol. 2015; 72(2):185-93. DOI: 10.1007/s00228-015-1968-y. View

20.

Horinkova J, Sima M, Slanar O . Pharmacokinetics of Dasatinib. Prague Med Rep. 2019; 120(2-3):52-63. DOI: 10.14712/23362936.2019.10. View